HMR Refludan Reduces New Thromboembolic Complications By 70%
Executive Summary
Hoechst Marion Roussel's Refludan reduces the risk of new thromboembolic complications to 6.3% after one week of treatment, compared with a 22.2% risk for historical control patients with heparin-induced thrombocytopenia, labeling states.